GlassScriptPhysician profile
Eliot Bassett
NPI 1750768875
$1,808.01
in general payments reported to CMS, 2019-2025
13 companies · $386 in 2025
The $386 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $76.95 · 2023: $731 · 2024: $614 · 2025: $386.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,731.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,731.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $716.45 | 2023-2025 | Fetroja |
| Pfizer INC. | $196.52 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $187.52 | 2022-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $153.02 | 2022-2025 | Zerbaxa, Recarbrio, Dificid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $137.40 | 2023-2025 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $92.53 | 2023-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.93 | 2022-2023 | Jardiance |
| Boston Scientific Corporation | $62.37 | 2023 | Watchman Access System |
| Abbvie INC. | $60.95 | 2023-2025 | Teflaro |
| Ucb, INC. | $51.02 | 2023-2024 | Briviact |
| Astrazeneca Pharmaceuticals LP | $27.19 | 2022-2023 | Lokelma |
| Takeda Pharmaceuticals U.S.A., INC. | $26.50 | 2025 | Vpriv |
| Route 92 Medical, INC. | $18.61 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eliot Bassett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.